Sandoz: US Oral Solids And Injectables Have Reached Bottom
Novartis Unit Also Aiming To Move Up Value Chain As Standalone Business
Following Novartis’ announcement that it intended to spin-off its Sandoz business into a standalone company, management from both firms commented on several key issues facing Sandoz, including the US pricing and environment and arrangements for manufacturing.
